Murine study finds potential boost for ovarian cancer drug Olaparib
Wednesday, January 25, 2017 - 14:01
in Health & Medicine
Researchers have discovered that the metabolic enzyme phosphoglycerate mutase 1 (PGAM1) helps cancer cells repair their DNA and found that inhibiting PGAM1 sensitizes tumors to the cancer drug Olaparib (Lynparza). Their findings suggest that this FDA-approved ovarian cancer medicine has the potential to treat a wider range of cancer types than currently indicated.